Preclinical Biologic Assessment of Proton Beam Relative Biologic Effectiveness at Proton Therapy Center Houston
- Department of Experimental Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
- Department of Radiation Physics, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
- Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
The clinical use of protons for the treatment of cancer is one of the most technologically advanced forms of therapy. The newly commissioned M.D. Anderson Cancer Center, Proton Therapy Center Houston is one of the newest facilities offering a complete range of advanced proton therapies designed specifically to minimize treatment-related normal tissue toxicity. As an integral part of the clinical commissioning of this proton beam, we performed an in vivo assessment of the relative biologic effectiveness of the 250-MeV protons relative to standard cobalt {sup 60} using the jejunal crypt microcolony assay in mice. Our data are consistent with a generic relative biologic effectiveness of 1.1, and this relative biologic effectiveness is in agreement with that used to describe most other clinical proton therapy beams worldwide.
- OSTI ID:
- 20951728
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 68, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2007.03.051; PII: S0360-3016(07)00570-6; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
SU-E-T-280: Dose Evaluation in Using CT Density Versus Relative Stopping Power for Pencil Beam Planning and Treating IROC Proton Phantom
Relative Biological Effectiveness Variation Along Monoenergetic and Modulated Bragg Peaks of a 62-MeV Therapeutic Proton Beam: A Preclinical Assessment